newsfilter
← Latest News
GlobeNewswire·

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

  • DBV Technologies filed its 2025 Annual Report on Form 10-K with the U.S. SEC & its 2025 Universal Registration Document with the French AMF.
  • The 2025 URD includes the annual financial report, corporate governance report, share buy-back program description, statutory auditor reports, & auditor fee information.
  • Documents are accessible on the company's website (www.dbv-technologies.com), the SEC website, & the AMF website.
  • The company is a late-stage biopharmaceutical firm developing VIASKIN® patch technology for food allergies via epicutaneous immunotherapy.
  • VIASKIN® Peanut Patch clinical trials are ongoing for peanut-allergic toddlers (ages 1-3) & children (ages 4-7).
  • DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ.
  • Ordinary shares trade on Euronext Paris (DBV) & ADSs trade on the Nasdaq Capital Market (DBVT).